Overview

Efficacy and Safety of Partial Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Status:
Not yet recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection partial substitution of glucocorticoid in patients with ANCA-associated vasculitis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Collaborator:

Beijing Defengrei Biotechnology Co.,Ltd

Treatments:

Cyclophosphamide
Glucocorticoids
Prednisone